Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Omeros Corp. OMER

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$-3.4M
$-116.2M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

On November 25, 2025, Omeros completed a transaction in which Novo Nordisk Healthcare AG received exclusive global rights in all indications to develop and commercialize its lead investigational MASP-3 inhibitor, zaltenibart (formerly OMS906), and certain related compounds and products. As of December 31, 2025, the company had 175 full-time employees, 116 of whom are in research and development, 15 of whom are in sales and marketing and 44 of whom are in finance, legal, business development and administration. The company was incorporated in 1994 as a Washington corporation, with its principal executive offices located at 201 Elliott Avenue West, Seattle, Washington.

Written from the business description in OMEROS CORP's annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth

·
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2020 · Revenue 73.8 · Net income -138.1
50M100M-50M-100M
2009201220152018202120242025
Compound annual growth
+4.4%
+40.4%
+42.7%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +40.4% a year over the five years to FY2020.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2020 · Operating -212.6% · Net -187.0%
-5000%-10000%
200920172025
ROE
FY2022 · ROE 86.6%
50%-50%
200920172025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.

Return on equity has no reading this year — return on capital employed, just below, still does: -55%.

Cash & shareholders

USD 0.00
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -116.2
30M60M-100M-200M
200920172025
Net buybacks $M Dividends $M
FY2025 · Dividends · · Net buybacks -7.7
5M10M-3M-6M
20212022202320242025

Total assetsUSD 325.6M
EquityUSD -121.2M
CashUSD 9.7M
Gross debtUSD 87.9M
Net debtUSD 78.2M
Current ratio2.76×

Equity was zero or negative — liabilities equaled or exceeded assets. No ratio is shown.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
OMER, 17-year financial record
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B◌◌◌◌◌0.10.10.00.10.00.00.00.00.00.00.00.0
Operating income $B−0.1−0.2−0.2−0.2−0.2−0.2−0.1−0.1−0.0−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0
EBITDA $B−0.1−0.2−0.2−0.2−0.2◌◌◌◌◌◌−0.1−0.1−0.0−0.0−0.0◌
Income tax $B0.00.00.00.00.0−0.0−0.0−0.00.00.0◌◌◌◌◌◌◌
Net income $B−0.0−0.2−0.10.00.2−0.1−0.1−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.1−0.10.1−0.1−0.1−0.1−0.1−0.1−0.0−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.05−2.70−1.880.763.12−2.41−1.71−2.61−1.17−1.65−2.00−2.22−1.39−1.59−1.29−1.37−2.92
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————————————
ROE %———86.6———————————−92.0−48.9
Shares out B0.070.060.060.060.060.060.050.050.050.040.040.030.030.030.020.02◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 65 reconciliationsAUDITED

Reconciled in 17 of the 17 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Six checks were skipped: cost of revenue is not tagged before 2013. Three checks were skipped: the share count is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inWashington
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image